Nevertheless, these recent advances in OV-mediated ICI delivery have substantially expanded the options available for delivering PD-1/PD-L1 ICIs preferentially to tumor tissues, whilst simultaneously sensitizing them to PD-1/PD-L1 ICIs by stimulating ICD. The gene discussed is CD274; the disease is neoplasm.